These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11274021)

  • 1. Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing.
    Piironen T; Nurmi M; Irjala K; Heinonen O; Lilja H; Lövgren T; Pettersson K
    Clin Chem; 2001 Apr; 47(4):703-11. PubMed ID: 11274021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of free prostate-specific antigen (PSA) after chemical release from the complex with alpha(1)-antichymotrypsin (PSA-ACT).
    Peter J; Unverzagt C; Hoesel W
    Clin Chem; 2000 Apr; 46(4):474-82. PubMed ID: 10759471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease.
    España F; Martínez M; Sánchez-Cuenca J; Vera CD; Estellés A; Jiménez-Cruz JF
    Eur Urol; 1996; 30(4):512-8. PubMed ID: 8977078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples.
    Piironen T; Pettersson K; Suonpää M; Stenman UH; Oesterling JE; Lövgren T; Lilja H
    Urology; 1996 Dec; 48(6A Suppl):81-7. PubMed ID: 8973706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
    Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
    Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum.
    Zhang WM; Finne P; Leinonen J; Vesalainen S; Nordling S; Stenman UH
    Clin Chem; 1999 Jun; 45(6 Pt 1):814-21. PubMed ID: 10351990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer.
    Tanaka M; Suzuki Y; Takaoka K; Murakami S; Suzuki N; Shimazaki J
    Int J Urol; 1999 Dec; 6(12):600-6. PubMed ID: 10609542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum.
    Björk T; Ljungberg B; Piironen T; Abrahamsson PA; Pettersson K; Cockett AT; Lilja H
    Urology; 1998 Jan; 51(1):57-62. PubMed ID: 9457289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
    Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
    Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
    Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
    Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.
    Jung K; Lein M; Brux B; Sinha P; Schnorr D; Loening SA
    Clin Chem Lab Med; 2000 Dec; 38(12):1271-5. PubMed ID: 11205692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
    Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.
    Mitrunen K; Pettersson K; Piironen T; Björk T; Lilja H; Lövgren T
    Clin Chem; 1995 Aug; 41(8 Pt 1):1115-20. PubMed ID: 7543033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
    Saika T; Tsushima T; Nasu Y; Kusaka N; Miyaji Y; Takamoto H; Takeda K; Uno S; Kumon H;
    Cancer; 2002 Mar; 94(6):1685-91. PubMed ID: 11920529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.